N1087

Eurofarma Laboratorios S.A. · Phase 3 active Small molecule

The mechanism of action for N1087 is currently unknown.

At a glance

Generic name	N1087
Sponsor	Eurofarma Laboratorios S.A.
Modality	Small molecule
Phase	Phase 3

Mechanism of action

As of now, there is insufficient information available to describe the specific mechanism of action for N1087.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of N1087 in Participants With Female Pattern Hair Loss (MINORA-WOMEN) (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

N1087 CI brief — competitive landscape report
N1087 updates RSS · CI watch RSS
Eurofarma Laboratorios S.A. portfolio CI